Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helixor P infusion therapy for cancer-related fatigue in advanced breast cancer and NSCLC
DRKS00016937Phase 2Terminated
- Sponsor
- Helixor Heilmittel GmbH
- Start
- Mar 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of viscum album extract in breast cancer and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Helixor Heilmittel GmbH. Primary endpoint: Change in cancer-related fatigue. Started Mar 2019; status: terminated.
02
Drugs
viscum album extract
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on DRKS00016937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00016937.